# Progress Note 07 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lili Boulanger (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET025-SYN
- Date: 2026-10-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odile Marchetti-Rowe, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning) on the same day

## Chief complaint

Adult preventive visit; no new complaints. **S**

## History of present illness

Ms. Boulanger, now 22, returns for her yearly preventive visit. Her Crohn disease is in remission on risankizumab every eight weeks, with her last injection a week ago. The follow-up ileocolonoscopy two weeks ago showed healed ulcers (SES-CD 2). She has one or two formed stools a day, no pain, and has regained her weight. Her periods have become regular again. She is composing most mornings and has a new choral work in rehearsal. She completed the health risk assessment before the visit. **S**

| Element | Detail |
|---|---|
| Visit | Adult preventive visit, age 22 |
| Active conditions | Ileocolonic Crohn disease in remission on risankizumab |
| Medicines | Risankizumab 360 mg every 8 weeks; vitamin D3 2000 units daily |
| Recent events | Ileocolonoscopy two weeks ago: endoscopic response, SES-CD 2 |
| Functional status | Independent; composing and rehearsing |

## Health risk assessment

Completed by the patient before the visit and reviewed during the visit. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good, better than at any time she can remember |
| Psychosocial | Supportive friends and fellow musicians; feels safe at home; some worry about money from a year of reduced work |
| Behavioral | Never smoker; no alcohol; no drugs; walks daily; eating three meals with snacks |
| Sexual and reproductive health | Not sexually active; no pregnancy plans for the next few years; contraception discussed |
| Activities of daily living | Independent in all |
| Instrumental activities of daily living | Manages her own medicines, injections, money, and household |
| Home safety | Smoke detector working; wears a seat belt |
| Sleep | About eight hours a night |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight regained; no fever or night sweats |
| Eyes | Negative | No red or painful eyes |
| Ears, nose, mouth, and throat | Negative | No mouth ulcers |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough |
| Gastrointestinal | Negative | One or two formed stools a day; no pain or blood |
| Genitourinary | Negative | Regular periods; no urinary symptoms |
| Musculoskeletal | Negative | No joint pain or swelling |
| Integumentary | Negative | No rash, tender nodules, or new moles |
| Neurological | Negative | No headaches or numbness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

11 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs **S**
- Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12 **S**
- Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 51.4 kg; BMI 20.1 kg/m². All vital signs are synthetic.

PHQ-2: 0; AUDIT-C: 0. All results are synthetic.

## Change since baseline

- PHQ-2: 2 at baseline, 0 at this visit **S**

## Immunizations given today

- Influenza vaccine, 2026-2027 season **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well-appearing; BMI 20.1 |
| Eyes | Conjunctivae clear |
| Mouth | No ulcers |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Soft, non-tender; no mass |
| Skin | No erythema nodosum; no suspicious lesions |
| Musculoskeletal | No joint swelling |
| Psychiatric | Bright and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Adult preventive visit completed**. Health risk assessment reviewed and a written prevention plan given. Depression and alcohol screens negative. **S**
   - Next preventive visit in one year.
2. **Crohn disease in remission on risankizumab** (K50.80). Clinical, biochemical, and endoscopic response. **S**
   - Continue risankizumab every 8 weeks.
   - IBD review with calprotectin every six months.
3. **Contraception and pregnancy planning**. Not sexually active and no pregnancy plans now. **S**
   - Contraception options reviewed for when she needs them; a levonorgestrel IUD or implant are the most effective and do not affect Crohn disease.
   - Preconception IBD review before any planned pregnancy, after at least three to six months of steroid-free remission; folic acid from three months before.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, 2026-2027 | Completed today | Inactivated vaccine given today; recommended yearly on biologic therapy |
| COVID-19 vaccine, 2026-2027 | Due | Recommended on immunosuppressive therapy; she will get it at her pharmacy next week |
| Pneumococcal vaccine | Up to date | PCV20 in January, before treatment; no further doses needed |
| Recombinant zoster vaccine | Up to date | Two doses completed, in January and April |
| Hepatitis B immunity | Up to date | Booster in January; anti-HBs protective in April |
| HPV vaccine | Up to date | Series completed in adolescence |
| Tetanus booster | Up to date | Tdap ten years ago at 12; next due now to within a year |
| Live vaccines (MMR, varicella) | Not indicated | Immune by serology; live vaccines are avoided on risankizumab |
| Cervical cancer screening | Completed today | First cervical cytology at 22, done today; women on immunosuppressive therapy may need closer screening, to be set by the result |
| Skin cancer prevention | Completed today | Sun protection advised; skin examination today normal |
| Chlamydia and gonorrhea screening | Not indicated | Not sexually active; offered when that changes |
| HIV, hepatitis B, and hepatitis C screening | Up to date | Negative before treatment in January |
| Bone health | Up to date | DXA in January within the expected range; vitamin D now normal; no repeat needed unless more steroids are required |
| Depression and anxiety screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol and drug use screening | Completed today | AUDIT-C 0; no drug use |
| Tobacco use | Completed today | Never smoker; smoking worsens Crohn disease, and she was counseled never to start |
| Blood pressure screening | Completed today | 108/68 mmHg |
| Physical activity and diet counseling | Completed today | Daily walking, a varied diet now that she is in remission, and calcium from food |

## Advance care planning

Voluntary advance care planning discussion of about 15 minutes, with her consent, prompted by a chronic illness treated with immunosuppression. She named a close friend as her health care agent and will complete a written health care directive at home. She would want full treatment for any serious illness from which she could expect to recover and return to composing. **S**

## Guideline basis

- ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025), American College of Gastroenterology
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force

## Follow-up

- Cervical cytology result by portal message. COVID-19 vaccine at her pharmacy. Next risankizumab dose in seven weeks. IBD review in four months. **S**

